Pelikas Healthcare Private Limited

Wegovy (Semaglutide) 1.0mg FlexTouch solution for injection in pre-filled pen

Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity), or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Wegovy (Semaglutide) 1.0mg FlexTouch solution for injection in pre-filled pen

Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity), or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Wegovy (Semaglutide) 1.0mg FlexTouch solution for injection in pre-filled pen

Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity), or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Yurpeak KwikPen is a once-weekly injection administered subcutaneously in the abdomen, thigh, or upper arm. It’s essential to rotate injection sites to prevent skin irritation and ensure the proper absorption of the medicine. Take the injection on the same day each week and at the same time, as missing doses or inconsistent use may reduce the effectiveness of the medicine.

Always follow your doctor’s instructions about the dosage, timings, use, and storage of Yurpeak KwikPen. Keep the medicine in a refrigerator (2°C–8°C), but do not freeze it. If left out at room temperature, consult your pharmacist to determine if it is safe to use.

Yurpeak KwikPen is a once-weekly injection administered subcutaneously in the abdomen, thigh, or upper arm. It’s essential to rotate injection sites to prevent skin irritation and ensure the proper absorption of the medicine. Take the injection on the same day each week and at the same time, as missing doses or inconsistent use may reduce the effectiveness of the medicine.

Always follow your doctor’s instructions about the dosage, timings, use, and storage of Yurpeak KwikPen. Keep the medicine in a refrigerator (2°C–8°C), but do not freeze it. If left out at room temperature, consult your pharmacist to determine if it is safe to use.

Rybelsus 7mg Tablet is a prescription medicine used to improve blood sugar (glucose) in adults with type 2 diabetes. It works by helping the body release insulin when needed, reducing sugar release by the liver, and slowing food digestion. Proper blood sugar control helps prevent serious diabetes complications.

Wegovy (Semaglutide) 1.0mg FlexTouch solution for injection in pre-filled pen

Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity), or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Wegovy (Semaglutide) 1.0mg FlexTouch solution for injection in pre-filled pen

Wegovy 1.0mg is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity), or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).